Details for Patent: 8,921,514

Title:	Anti-viral compounds
Abstract:	Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Inventor(s):	DeGoey; David A. (Salem, WI), Kati; Warren M. (Gurnee, IL), Hutchins; Charles W. (Green Oaks, IL), Donner; Pamela L. (Mundelein, IL), Krueger; Allan C. (Gurnee, IL), Randolph; John T. (Libertyville, IL), Motter; Christopher E. (Oak Creek, WI), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Matulenko; Mark A. (Libertyville, IL), Keddy; Ryan G. (Beach Park, IL), Jinkerson; Tammie K. (Pleasant Prairie, WI), Gao; Yi (Vernon Hills, IL), Liu; Dachun (Vernon Hills, IL), Pratt; John K. (Kenosha, WI), Rockway; Todd W. (Grayslake, IL), Maring; Clarence J. (Palatine, IL), Hutchinson; Douglas K. (Antioch, IL), Flentge; Charles A. (Salem, WI), Wagner; Rolf (Antioch, IL), Tufano; Michael D. (Chicago, IL), Betebenner; David A. (Grayslake, IL), Sarris; Kathy (Mundelein, IL), Woller; Kevin R. (Antioch, IL), Wagaw; Seble H. (Evanston, IL), Califano; Jean C. (Whitefish Bay, WI), Li; Wenke (Gurnee, IL), Caspi; Daniel D. (Evanston, IL), Bellizzi; Mary E. (Lake Forest, IL), Carroll; William A. (Evanston, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Filing Date:	Dec 09, 2010
Application Number:	12/964,027
Claims:	1. A compound having Formula I, or a pharmaceutically acceptable salt thereof, ##STR00832## wherein: X is C.sub.3-C.sub.12carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more R.sub.A; L.sub.1, L.sub.2, and L.sub.3 are bond; A is 5- to 6-membered heterocycle; B is C.sub.3-C.sub.12carbocycle or 3- to 12-membered heterocycle; D is phenyl, and is optionally substituted with one or more R.sub.A; Y is --C(R.sub.1R.sub.2)N(R.sub.5)--C(O)-L.sub.Y-N(R.sub.B'')C(O)-L.sub.S-R.su- b.E, wherein L.sub.Y is C.sub.1-C.sub.6alkylene, and R.sub.B'' is hydrogen; R.sub.1 is hydrogen, and R.sub.2 and R.sub.5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle; Z is --C(R.sub.8R.sub.9)N(R.sub.12)--C(O)-L.sub.Y-N(R.sub.B'')C(O)-L.sub.S-R.s- ub.E, wherein L.sub.Y and R.sub.B'' are as defined above; R.sub.8 is hydrogen, and R.sub.9 and R.sub.12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle; R.sub.A is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L.sub.S-R.sub.E, wherein two adjacent R.sub.A, taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, can optionally form carbocycle or heterocycle; R.sub.E is independently selected at each occurrence from --O--R.sub.S, --S--R.sub.S, --C(O)R.sub.S, --OC(O)R.sub.S, --C(O)OR.sub.S, --N(R.sub.SR.sub.S'), --S(O)R.sub.S, --SO.sub.2R.sub.S, --C(O)N(R.sub.SR.sub.S'), --N(R.sub.S)C(O)R.sub.S', --N(R.sub.S)C(O)N(R.sub.S'R.sub.S''), --N(R.sub.S)SO.sub.2R.sub.S', --SO.sub.2N(R.sub.SR.sub.S'), --N(R.sub.S)SO.sub.2N(R.sub.S'R.sub.S''), --N(R.sub.S)S(O)N(R.sub.S'R.sub.S''), --OS(O)--R.sub.S, --OS(O).sub.2--R.sub.S, --S(O).sub.2OR.sub.S, --S(O)OR.sub.S, --OC(O)OR.sub.S, --N(R.sub.S)C(O)OR.sub.S', --OC(O)N(R.sub.SR.sub.S'), --N(R.sub.S)S(O)--R.sub.S', --S(O)N(R.sub.SR.sub.S') or --C(O)N(R.sub.S)C(O)--R.sub.S'; or C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl or C.sub.2-C.sub.6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C.sub.3-C.sub.6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl; L.sub.S is each independently selected at each occurrence from bond; or C.sub.1-C.sub.6alkylene, C.sub.2-C.sub.6alkenylene or C.sub.2-C.sub.6alkynylene; and R.sub.S, R.sub.S' and R.sub.S'' are each independently selected at each occurrence from hydrogen; C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl or C.sub.2-C.sub.6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R.sub.S, R.sub.S' or R.sub.S' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2' C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl. 2. The compound or salt according to claim 1, wherein R.sub.2 and R.sub.5, taken together with the atoms to which they are attached, form ##STR00833## and R.sub.9 and R.sub.12, taken together with the atoms to which they are attached, form ##STR00834## 3. The compound or salt according to claim 2, wherein B is 5- to 6-membered heterocycle. 4. The compound or salt according to claim 3, wherein X is a ring system comprising a 6- to 12-membered bicycle which is substituted with one or more R.sub.A, and wherein two adjacent R.sub.A, taken together with the atoms to which they are attached, form carbocycle or heterocycle. 5. The compound or salt according to claim 3, wherein D is phenyl. 6. The compound or salt according to claim 4, wherein D is phenyl. 7. A pharmaceutical composition comprising the compound or salt of claim 1.